Amneal Pharmaceuticals, Inc. is a U.S.-domiciled publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals was founded in 2002 by brothers Chirag and Chintu Patel. The company manufactured its first Rx product in 2005 and received its first ANDA approval in 2006.

Do Institutions Own Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Shares?

Amneal to Participate at Upcoming Investor Conferences in May

Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates

Amneal Reports First Quarter 2022 Financial Results

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

Amneal to Report First Quarter 2022 Results on May 4, 2022

Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting

Should You Be Concerned About Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) ROE?

Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries

Amneal Pharmaceuticals (AMRX) Lags Q4 Earnings Estimates

Amneal Reports Fourth Quarter and Full Year 2021 Financial Results

Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal Expands Injectables Portfolio with 4 New Products

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022

Shareholders in Amneal Pharmaceuticals (NYSE:AMRX) are in the red if they invested three years ago

Is Amneal Pharmaceuticals (AMRX) a Suitable Pick for Value Investors?

Amneal Acquires Saol Therapeutics Baclofen Franchise

Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference

Top Streaming News